Monoclonal Anti-MAGE-3 CTL Responses in Melanoma Patients Displaying Tumor Regression after Vaccination with a Recombinant Canarypox Virus

Journal of Immunology

Volumn 171, Issue 9, 2003, Pages 4898-4904

  Karanikas, Vaios ^a   Lurquin, Christophe ^b   Colau, Didier ^b   Van Baren, Nicolas ^b   De Smet, Charles ^b   Lethé, Bernard ^b   Connerotte, Thierry ^a   Corbière, Véronique ^a   Demoitié, Marie Ange ^a   Liénard, Danielle ^c   Dréno, Brigitte ^d   Velu, Thierry ^e   Boon, Thierry ^a,b   Coulie, Pierre G ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^d HÔTEL DIEU   (France)

^e ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CHROMIUM 51; COMPLEMENTARY DNA; MAGE 3 A1 PEPTIDE; MELANOMA VACCINE; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; CANARYPOX VIRUS; CYTOTOXIC T LYMPHOCYTE; GENE; HUMAN; HUMAN CELL; IMMUNIZATION; ISOTOPE LABELING; LYMPHOCYTE CLONE; MAGE 3 GENE; MELANOMA; MIXED LYMPHOCYTE CULTURE; MULTIGENE FAMILY; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR REGRESSION; VACCINATION; VIRUS RECOMBINANT;

EID: 10744230425     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.171.9.4898     Document Type: Article

References (24)

1. van der Bruggen, P., C. Traversari, P. Chomez, C. Lurquin, E. De Plaen, B. Van den Eynde, A. Knuth, and T. Boon. 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643.
2. Boon, T., and B. Van den Eynde. 2000. Cancer vaccines: cancer antigens, shared tumor-specific antigens. In Principles and Practice of the Biologic Therapy of Cancer. S. A. Rosenberg, ed. Lippincott Williams & Wilkins, Philadelphia, p. 493.
3. Brasseur, F., D. Rimoldi, D. Liénard, B. Lethé, S. Carrel, F. Arienti, L. Suter, R. Vanwijck, A. Bourlond, Y. Humblet, et al. 1995. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int. J. Cancer. 63:375.
4. Van Der Bruggen, P., Y. Zhang, P. Chaux, V. Stroobant, C. Panichelli, E. Schultz, J. Chapiro, B. Van Den Eynde, F. Brasseur, and T. Boon. 2002. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol. Rev. 188:51.
5. + T lymphocytes. J. Exp. Med. 189:767.
6. , Chaux, P., R. Luiten, N. Demotte, V. Vantomme, V. Stroobant, C. Traversari, V. Russo, E. Schultz, G. R. Cornelis, T. Boon, and P. van der Bruggen. 1999. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. J. Immunol. 163:2928.
7. van der Bruggen, P., Y. Zhang, P. Chaux, V. Stroobant, C. Panichelli, E. S. Schultz, J. Chapiro, B. J. Van den Eynde, F. Brasseur, and T. Boon. 2002. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol. Rev. 188:51.
8. Schuler-Thurner, B., E. S. Schultz, T. G. Berger, G. Weinlich, S. Ebner, P. Woerl, A. Bender, B. Feuerstein, P. O. Fritsch, N. Romani, and G. Schuler. 2002. Rapid induction of tumor-specific type I T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J. Exp. Med. 195:1279.
9. Marchand, M., N. van Baren, P. Weynants, V. Brichard, B. Dréno, M.-H. Tessier, E. Rankin, G. Parmiani, F. Arienti, Y. Humblet, et al. 1999. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer 80:219.
10. Marchand, M., C. J. A. Punt, S. Aamdal, B. Escudier, W. H. J. Kruit, U. Keilholz, L. Håkansson, N. van Baren, Y. Humblet, P. Mulders, et al. 2003. Immunization of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: clinical report. Eur. J. Cancer 39:70.
11. Thurner, B., I. Haendle, C. Roder, D. Dieckmann, P. Keikavoussi, H. Jonuleit, A. Bender, C. Maczek, D. Schreiner, P. von den Driesch, et al. 1999. Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190:1669.
12. Baldo, M., M. Schiavon, P. A. Cicogna, P. Boccato, and F. Mazzoleni. 1992. Spontaneous regression of subcutaneous metastasis of cutaneous melanoma. Plast. Reconstr. Surg. 90:1073.
13. Coulie, P. G., V. Karanikas, C. Lurquin, D. Colau, T. Connerotte, T. Hanagiri, A. Van Pel, S. Lucas, D. Godelaine, C. Lonchay, et al. 2002. Cytolytic T cell responses of cancer patients vaccinated with a MAGE antigen. Immunol. Rev. 188:33.
14. Chaux, P., V. Vantomme, P. Coulie, T. Boon, and P. van der Bruggen. 1998. Estimation of the frequencies of anti-MAGE-3 cytolytic T lymphocyte precursors in blood from individuals without cancer. Int. J. Cancer 77:538.
15. Coulie, P. G., V. Karanikas, D. Colau, C. Lurquin, C. Landry, M. Marchand, T. Dorval, V. Brichard, and T. Boon. 2001. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc. Natl. Acad. Sci. USA 98:10290.
16. Cadoz, M., A. Strady, B. Meignier, J. Taylor, J. Tartaglia, E. Paoletti, and S. Plotkin. 1992. Immunisation with canarypox virus expressing rabies glycoprotein. Lancet 339:1429.
17. Paoletti, E., J. Tartaglia, and J. Taylor. 1994. Safe and effective poxvirus vectors-NYVAC and ALVAC. Dev. Biol. Stand. 82:65.
18. DiBrino, M., T. Tsuchida, R. V. Turner, K. C. Parker, J. E. Coligan, and W. E. Biddison. 1993. HLA-A1 and HLA-A3 T cell epitopes derived from influenza virus proteins predicted from peptide binding motifs. J. Immunol. 151:5930.
19. Altman, J. D., P. A. H. Moss, P. J. R. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, A. J. McMichael, and M. M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94.
20. Genevée, C., A. Diu, J. Nierat, A. Caignard, P. Y. Dietrich, L. Ferradini, S. Roman-Roman, F. Triebel, and T. Hercend. 1992. An experimentally validated panel of subfamily-specific oligonucleotide primers (V alpha 1-w29/Vβ1-w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction. Eur. J. Immunol. 22:1261.
21. Frey, S. E., F. K. Newman, J. Cruz, W. B. Shelton, J. M. Tennant, T. Polach, A. L. Rothman, J. S. Kennedy, M. Wolff, R. B. Belshe, and F. A. Ennis. 2002. Dose-related effects of smallpox vaccine. N. Engl. J. Med. 346:1275.
22. Godelaine, D., J. Carrasco, S. Lucas, V. Karanikas, B. Schuler-Thurner, P. G. Coulie, G. Schuler, T. Boon, and A. Van Pel. 2003. Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.AI peptide. J. Immunol. 171:4893.
23. Luiten, R. M., N. Demotte, J. Tine, and P. van der Bruggen. 2000. A MAGE-A1 peptide presented to cytolytic T lymphocytes by both HLA-B35 and HLA-A1 molecules. Tissue Antigens 56:77.
24. Schultz, E. S., Y. Zhang, R. Knowles, J. Tine, C. Traversari, T. Boon, and P. van der Bruggen. 2001. A MAGE-3 peptide recognized on HLA-B35 and HLA-A1 by cytolytic T lymphocytes. Tissue Antigens 57:103.